Who is sponsoring BEATSTEMIPi?

BEATSTEMIPi is sponsored by University Hospital, Basel, Switzerland.

What condition does BEATSTEMIPi study?

BEATSTEMIPi studies Acute Myocardial Infarction.

What drugs are being tested in BEATSTEMIPi?

Interventions: methoxy-polyethyleneglycol epoetin beta.

What is the status of BEATSTEMIPi?

BEATSTEMIPi is currently COMPLETED.

Last reviewed 2012-02-28 · How we verify

Documentation of Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial Infarction (BEAT-STEMI Pilot) (BEATSTEMIPi)

NCT01093820 Phase 2 COMPLETED

Hypothesis: Based on available pharmacokinetic data from healthy volunteers we hypothesize that the administration of a cumulative dose of 210μg of the continuous erythropoietin receptor activator, Mircera® (Roche), during 3 months post percutaneous coronary intervention (PCI) does not result in hemoglobin (Hb) levels \>15 g/dl in patients with ST-segment elevation myocardial infarction (STEMI) Design: Prospective, open label single center pilot study

Details

Lead sponsor	University Hospital, Basel, Switzerland
Phase	Phase 2
Status	COMPLETED
Enrolment	8
Start date	2010-04
Completion	2010-10

Conditions

Acute Myocardial Infarction

Interventions

methoxy-polyethyleneglycol epoetin beta

Primary outcomes

Proportion of patients exceeding Hemoglobin (Hb) of 15 g/L within 3 months — three months
measurement of Hb at baseline and month 1, 2 and 3

Countries

Switzerland